Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 15Neoplasm Metastasis 3HER2-positive Breast Cancer 2Brain Neoplasms 2Stomach Neoplasms 1Solid Cancer 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Liver Neoplasms 1Inflammatory Breast Neoplasms 1HER2-positive Early Breast Cancer 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma 1Cancer Related Cognitive Decline 1Breast Neoplasms, Male 1Breast Diseases 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pertuzumab 1Trastuzumab 1Rituximab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Meningeal Neoplasms × pertuzumab × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡